In a recent human positron emission tomography (PET) study we demonstrated the ability to detect amphetamine-induced dopamine (DA) 
INTRODUCTION
The displacement of the in vivo binding of D 2/3 receptor-specific SPECT and positron emission tomography (PET) radiotracers by an acute amphetamine challenge is used as a non-invasive measure to quantify dopamine (DA) release in the striatum. Combined microdialysis and imaging studies in non-human primates have validated this approach by demonstrating a linear dose-response relationship in which 1% reduction in [ 123 I]IBZM or [ 11 C]raclopride binding potential (BP ND ) corresponds to a 40% increase in extracellular DA. 1, 2 In the past two decades numerous clinical investigations have used this approach to report abnormal amphetamine-induced DA release in the striatum in neuropsychiatric disorders such as schizophrenia, 2, 3 ADHD 4 and addiction. 5, 6 The advancement of the PET radioligands [ 11 C]FLB 457 (K D ¼ 0.06 nM) and [ 18 F]fallypride (K D ¼ 0.14 nM), which bind to D 2/3 receptors with a relatively high affinity, led to the characterization of amphetamine-induced DA release in extrastriatal regions such as the midbrain, thalamus, hippocampus and cortex. [7] [8] [9] [10] We recently demonstrated the ability to detect amphetamine-induced DA release in the human cortex with [ 11 C]FLB 457 and PET. 9 In this study, amphetamine led to a significant reduction (range 4-13%) in [ 11 C]FLB 457 BP ND in several cortical regions of interest, including the dorsolateral prefrontal cortex, medial prefrontal cortex and anterior cingulate cortex. Since this initial report we have conducted a series of studies to validate the use of [ 11 C]FLB 457 PET as a non-invasive tool to measure DA release in the cortex. The results of these [ 11 C]FLB 457 studies suggest good reproducibility (o15%) for BP ND in the cortical regions of interest, 11 no carryover mass-induced decrease in BP ND in the imaging paradigm that is used to measure amphetamine-induced DA release in the cortex, 11 and a small but significant fraction of D 2/3 receptor-specific binding in the cerebellum (that is, the reference region which is used as an estimate of non-specific binding), which may impact the measurement (DBP ND ) of DA release in the cortex. 12 The [
11 C]FLB 457 PET-amphetamine paradigm was developed to demonstrate differences in amphetamine-induced DA release between patients and healthy controls in clinical imaging studies. Hence, a critical step in its validation is to document that the relationship between increase in DA concentration and decrease in [ 11 C]FLB 457 BP ND concentration in the cortex are amphetamine dose-dependent and linear, as demonstrated in the striatum. In addition, there are unique challenges to demonstrating this relationship in the cortex as opposed the striatum because there is less DA in the cortex. 13, 14 Finally, another observation that required investigation is the magnitude of amphetamineinduced displacement (0.5 mg kg À 1 ) of [ 11 C]FLB 457 in the frontal cortex (B12-15%) 9 in humans for it is comparable to that reported in the striatum (B10%) with [ 11 C]raclopride and [ 123 I]IBZM (for review see Laruelle 15 ). Although this seems discrepant based on the fact that the striatum receives greater dopaminegic projections from the ventral tegmental area/ substantia nigra relative to the frontal cortex, a possible explanation for the same percent reduction in BP ND after amphetamine is related to the relatively large differences in baseline DA between these regions. In other words, the greater vulnerability of the in vivo binding of a D 2/3 radioligand in the cortex, compared with the striatum, is explained by less occupancy of D 2/3 receptors by DA at baseline in the cortex. Therefore, to gain a better understanding of these issues we conducted simultaneous microdialysis and PET imaging in nonhuman primates.
In summary, the primary objective of this study was to 'calibrate' [ 11 C]FLB 457 displacement in the frontal cortex, that is, to establish the quantitative relationship between relative change in dialysate DA and change in [ 11 C]FLB 457 BP ND . In addition, the secondary objective was to contrast the sensitivity of DA to displace D 2/3 radiotracer binding in the cortex with that in the striatum.
MATERIALS AND METHODS

General design
All experiments were performed under a protocol that was reviewed and approved by the University of Pittsburgh Institutional Animal Care Use Committee. A total of 54 PET scans in five adult male rhesus monkeys (denoted A, B, C, D and E; average age of the animals was 10.7±0.7 years; average weight of the animals was 9.0±0.7 kg) are reported here. These 54 PET scans were acquired in 27 experimental sessions over the course of 18 months. A minimum of 1 week was allowed between experimental sessions in the same animal. Each experimental session included two PET scans: a test-scan and a retest scan in the reproducibility studies (n ¼ 10 scans); and a baseline scan and a post-amphetamine scan in the amphetamine studies (n ¼ 44 scans). Animals were euthanized following successful completion of the research procedures. 11 C]FLB 457 PET under test and retest conditions. The aim of these studies was to determine the length of the inter-scan interval (that is, time in minutes between the start of the test and retest scans) that is associated with no decrease in [ 11 C]FLB 457 BP ND. The inter-scan interval was a concern as the FLB 457 mass carried over from the baseline to post-amphetamine PET scan in itself could lead to a reduction in [ 11 C]FLB 457 BP ND, as it has a relatively high affinity for D 2/3 receptors. 9 Thus, the animals were studied under a test and retest condition both 135 (A and B) and 195 min apart (A, B and C) to determine the appropriate inter-scan interval for the amphetamine studies. Informed by the test-retest studies, the inter-scan interval between the baseline and post-amphetamine scans was maintained at 195 min. All animals underwent simultaneous DA microdialysis from the frontal cortex (medial wall of dorsal prefrontal cortex) during the baseline and post-amphetamine conditions. The experiments with the amphetamine 0.5 mg kg À 1 dose were repeated in 4/5 animals because this dose is also used in our human imaging paradigm. 16, 17 Simultaneous microdialysis and PET data were successfully acquired in 14/20 experiments. Failure of microdialysis experiments was generally due to the inability to obtain baseline DA measurements. The most common reason for failure of PET experiments was the inability to synthesize an adequate dose (B1 mCi) of [ 11 C]FLB 457 at the mass limit (0.008 mg kg À 1 ) that was required for tracer dose. 18 Microdialysis/PET experiments that failed to provide usable data for a given dose of amphetamine during the simultaneous session were repeated at least once in a separate (that is, non-simultaneous) session to make up for the lost data point in each animal. An exception was a microdialysis experiment with amphetamine 0.5 mg kg À 1 in animal B, which could not be repeated due to removal of that animal from the study because of a fatal non-study-related cardiac event. The breakdown of n ¼ 20 PET and n ¼ 18 microdialysis experiments, 14 of which were acquired in simultaneous sessions in five animals is provided in Table 1 . 
Microdialysis methods
The microdialysis methods used in the construction of guide cannulae and probes have been previously described. [19] [20] [21] [22] [23] All animals underwent a stereotactic surgical procedure for placement of a polysulfone recording chamber (Crist Instruments, Damascus, MD, USA) that directs the insertion of the microdialysis probes. 19 Microdialysis probe trajectories to access the regions of interest (frontal cortex or striatum) were guided by a postsurgical computerized tomography (CT) scan co-registered to the subject's MRI. Under ketamine anesthesia, microdialysis probes were placed in sites, which had not been previously sampled, the day before the experiment as previously described. 19 Two probes were placed-one in the right and another in the left region of interest. The data from the right and left regions of interest were averaged when the microdialysis was successful from both of the probes. After lowering the probe, a protective cap was used to cover the chamber overnight. The following day, the cap was removed, and inlet and outlet lines were attached to the probe for microdialysis. Probes were held in place by a snug fit and were prevented from rotating by a tab. The solution used to perfuse the probe at 1.0 ml min À 1 was in mM: KCl 2.4, NaCl 137, CaCl2 1.2, MgCl2 1.2 and NaH2PO4 0.9, pH 7.4; ascorbate 0.2. DA in the perfusates was then determined using high-performance liquid chromatography as previously described. 19 Using these procedures dialysate DA was sampled every 10 min from the regions of interest during the baseline and postamphetamine conditions. Dialysate DA concentration was measured as nanomolar (nM) in dialysate without correction for in vitro recovery. There are two reasons for not using in-vitro recovery corrected values to estimate Imaging of cortical dopamine transmission R Narendran et al extracellular DA concentrations. First, an aqueous solution is a poor model of the actual extracellular environment in which diffusion occurs within a tortuous environment dominated by cell surface glycosaminoglycans with fixed anionic sites. 24 Second, it has been previously demonstrated that the 'no-net-flux' in vivo estimates of true extacellular concentrations correlate better with uncorrected dialysate levels than with in-vitro calibration corrected dialysate measures. 25 The time constraints of the combined microdialysis PET procedures did not permit the use of 'no-net-flux' extracellular values. Because we did not perform any correction for in vitro recovery and did not adopt the 'no-net flux' methodology, we refer to the DA concentration that was measured during the microdialysis experiments as change in 'dialysate DA ' rather than 'extracellular DA ' in this manuscript.
Amphetamine-induced increases in DA concentration (DDA) in dialysate were expressed as a percent increase in DA release relative to the mean baseline DA concentration (measured from À 30 to 0 min before amphetamine). The peak DDA (%) in the frontal cortex and striatum was used as the primary outcome measure for microdialysis in correlations with amphetamine-induced displacement of [
11 C]FLB 457 and [
11 C]raclopride. Our rationale for choosing the peak DA release rather than an average DA release (which is comparable to the area under curve because dialysate samples were collected at regular 10 min intervals) was based on the fact that there is a significant temporal discrepancy between the change in dialysate DA (as measured with microdialysis) and reduction in D 2/3 radiotracer BP ND (as measured with PET) due to the agonist-induced internalization of D 2/3 receptors following an acute amphetamine challenge. 1, [26] [27] [28] [29] Given this temporal disconnect between the microdialysis and PET outcome measures, it is likely that the reduction in BP ND following amphetamine is represented better by the peak rather than an average DDA (%) release. Furthermore, the use of peak DA release as the primary outcome measure in correlations with DBP ND is consistent with our previous report that evaluated amphetamine-induced DA release in the striatum. 1 The average DDA in the frontal cortex and striatum was calculated and used as a secondary outcome measure for microdialysis in the correlations with amphetamine-induced displacement of [
11 C]raclopride.
Imaging methods
Structural MRI. Each animal underwent a structural MRI scan using a Siemens 3T Allegra scanner for proper localization of regions of interest before the PET and microdialysis procedures. ]raclopride were carried out as previously described. 31, 32 PET imaging protocol. Fasted animals were immobilized with ketamine (10 mg kg À 1 intramuscularly, B90 min before the first [ 11 C]FLB 457 injection) and anesthetized with 1 to 2% isoflurane via endotracheal tube. The animals' vital signs were monitored every 10 min and temperature was kept constant at 37 1C with heated water blankets. An intravenous perfusion line was placed in each animal for hydration, injection of radiotracers and amphetamine. Head was positioned at the center of the field of view as defined by imbedded laser lines. PET imaging was performed with ECAT EXACT HR þ scanner (Siemens/CTI, Knoxville, TN, USA). A 10-min transmission scan was obtained before radiotracer injection for attenuation correction. Activity was injected intravenously over 30 s as a bolus. The injected FLB 457 and raclopride mass had upper limits of 0.008 mg kg À 1 and 0.1 mg kg À 1 , respectively. Emission data were collected in three -dimensional mode for 75 min as successive frames (20 frames Image analysis. PET data were reconstructed using filtered back-projection and corrected for photon attenuation, scatter 33 and radioactive decay. Reconstructed image files were then processed with the image analysis software MEDx (Sensor Systems, Inc., Sterling, Virginia) and SPM2 (www.fil.ion.ucl.ac.uk/spm). MR-PET image alignment was performed using a mutual information algorithm implemented in SPM2. Regions of interest including the frontal cortex (the frontal cortex was drawn as a single region to include the dorsolateral prefrontal cortex, medial prefrontal cortex, orbital frontal cortex and anterior cingulate cortex), striatum and cerebellum were subsampled on the structural MRI and then transferred to the co-registered PET scan. Time activity curves were generated for the frontal cortex (for [ 11 C]FLB 457) or striatum (for [ 11 C]raclopride) and cerebellum using the criteria and methods outlined previously. 34 Activity from the right and left regions of interest was averaged.
The Amphetamine plasma levels. Amphetamine plasma levels were measured in the PET experiments in three venous samples À 5 min, 35 min and 70 min after the amphetamine injection to contrast the concentrations at the 0.3, 0.5 and 1.0 mg kg À 1 doses. The analysis of these samples were conducted using previously described methods. 36 For technical reasons, amphetamine levels were not obtained in one of the 0.5 mg kg À 1 dose experiments.
Statistical analysis
All statistical analysis was performed with PASW Statistics 18.0 (SPSS Inc., Chicago, IL, USA). The differences in scan variables (such as injected mass and dose) between the baseline and amphetamine conditions were contrasted using paired t-tests. The effect of amphetamine on DDA (expressed as % of baseline levels) was evaluated using a non-parametric one-way (Kruskal-Wallis) analysis of variance (ANOVA) with amphetamine dose as factor. The effect of amphetamine on BP ND was evaluated using a repeated measures ANOVA (RM ANOVA), with the BP ND as dependent variable, the baseline and post-amphetamine conditions as within-subject factors, and the amphetamine dose and animal as between-subject factors. The significance levels for condition, condition*dose, condition*animal, condition*dose*animal interactions are reported. Correlations between DDA and DBP ND were performed using Pearson product moment correlation coefficient. A two-tailed P ¼ 0.05 was selected as the significance level for all tests. All values are expressed as mean ± s. Table 3 . Also, included in Table 3 are the frontal cortical DA concentrations (nM) at baseline, the peak DDA and average DDA after amphetamine as measured using microdialysis.
Amphetamine significantly increased DA concentrations in the dialysate in a dose-dependent manner (one-way ANOVA, peak DDA: H ¼ 7.895, df ¼ 2, P ¼ 0.019; average DDA: H ¼ 7.604, df ¼ 2, P ¼ 0.022) as shown in Figure 1 and Table 4 . Also, included in Table 4 are the striatal DA concentrations (nM) at baseline, the peak DDA and average DDA after amphetamine in the same animals.
Amphetamine plasma levels. The mean amphetamine plasma levels at 5 min, 35 independent cohorts by both us 37 and others. 38 An important validation step in using . The results of this simultaneous microdialysis and PET imaging study in non-human primates showed a linear relationship between increases in dialysate DA and decreases in [
11 C]FLB 457 BP ND in the frontal cortex consistent with that reported in the striatum. 1, 2 This supports the use of the [ 11 C]FLB 457-amphetamine imaging paradigm as a non-invasive tool to measure cortical DA release.
In this study, the correlation between microdialysis and PET outcome measures in the frontal cortex suggests that a 1% reduction in [ 11 C]FLB 457 binding corresponds to 57% increase in dialysate peak DA concentration (Figure 2 ). These data are comparable with the 1:40 to 1:64 (DBP ND : DDA) ratio that has been reported for [
123 I]IBZM and [ 11 C]raclopride in the striatum. 1, 2 Although, the correlations between DDA and DBP ND within a particular region is useful to interpret imaging data, a simple contrast of this ratio from the striatum and cortex is less informative. This is because the normalization of amphetamineinduced increases in DA to the baseline DA in the dialysis outcome measure used in these correlations fails to reflect the relatively large difference in the concentration of DA that is released in the striatum versus frontal cortex. In contrast, the relationship between the absolute increase in dialysate DA concentration and decrease in D 2/3 radiotracer BP ND in the striatum and frontal cortex represents the sensitivity of DA to inhibit radiotracer binding in these regions. To establish this relationship, two of the five animals underwent striatal DA microdialysis and [ 11 C]raclopride PET scans, both before and after amphetamine 0.5 mg kg À 1
. It was necessary to use [ 11 C]raclopride because the relatively slow kinetics of [ 11 C]FLB 457 does not allow for the estimation of BP ND in the striatum within the duration of a typical 60 to 120 min [C-11] PET scan. The absolute increase in peak dialysate DA concentration (i.e., difference between postamphetamine and baseline DA concentration) following amphetamine 0.5 mg kg À 1 was calculated for the frontal cortex and striatum using the data in Tables 3 and 4 . These data suggest that 14.2 nM increase in dialysate DA is associated with 1% reduction in [ 11 C]raclopride BP ND in the striatum (calculated as absolute increase in peak DA concentration/[ 11 C]raclopride displacement ¼ 523 nM/36.8%); and 0.21 nM increase in dialysate DA is associated with 1% reduction in [
11 C]FLB 457 BP ND in the frontal cortex (3.3 nM/15.5%). Thus, DA is more efficient in inhibiting D 2/3 receptor binding in the cortex compared to the striatum. The likely reason for the increased sensitivity of DA to inhibit cortical D 2/3 binding is that baseline DA levels are lower in this region compared to the striatum. Consistent with this notion are the results of imaging studies in healthy humans that have failed to detect significant occupancy of D 2/3 receptors by DA in the cortex with the alpha-methyl-para-tyrosine-induced DA depletion paradigm. 8, 41, 42 The same AMPT-induced DA depletion paradigm suggests that 10-15% of D 2/3 receptors are occupied by DA in the striatum. 43, 44 This explains the similar reduction in BP ND (B10%) observed in both these regions in humans after amphetamine (oral, 0.5 mg kg À 1 ) despite the fact that DA release is much lower in the cortex compared to the striatum (150-fold difference in absolute concentration change, based on the above data). In summary, despite the differences in sensitivity between striatum and cortex, [ 11 C]FLB 457-amphetamine studies in neuropsychiatric disorders such as schizophrenia and addiction should be able to use the 1: 57 ratio established in this study to quantitate the differences in cortical DA release that exist between patients and controls.
In contrast to the 6 to 24% decrease in [ 11 C]FLB 457 BP ND observed after 0.3 to 1.0 mg kg À 1 of amphetamine, the mean change in [
11 C]FLB 457 BP ND in the absence of amphetamine (test-retest scans, 195 min apart ) was only 0.5±1.7%. Due to a concern that the FLB 457 mass carried over from the baseline to the post-amphetamine scan in itself would lead to a reduction in BP ND , the demonstration of no effect on [
11 C]FLB 457 BP ND in the imaging paradigm that is used to measure amphetamine-induced DA release was necessary. Consistent with this concern, the test and retest scans performed 135 min apart showed a reduction in 11 C]FLB 457 (10-fold higher than current study), and measurement of specific to non-specific binding ratios under nonequilibrium conditions (no modeling approach was used to derive BP ND ) make it difficult to compare these results with the current Mean values of n ¼ 3-4 baseline dopamine samples from À 30 to 0 min before amphetamine.
Imaging of cortical dopamine transmission R Narendran et al study. 45 Another non-human primate study that used intravenous methamphetamine (2.0 mg kg À 1 ) to measure DA release reported a non significant reduction ( À 3.0±5.1%) in [ 11 C]FLB 457 BP ND in the frontal cortex. 46 Despite the several strengths of this study that demonstrated low variability for [ 11 C]FLB 457 BP ND in the frontal cortex in test-retest studies, administration of less injected mass (only two-fold higher than current study), and use of robust modeling methodology to derive BP ND, the investigation failed to report results consistent with this study. One reason for the inability to detect a significant effect for methamphetamine is inadequate power due to the limited number of experimental observations (n ¼ 3 animals in which DBP ND was þ 6, À 4, and À 12% after methamphetamine). Another possible reason is that methamphetamine-induced changes in non-specific binding (V ND ) may have led to an underestimation of DBP ND. This is a limitation of the current study as well, in which amphetamine-induced changes in V ND and its potential impact on the outcome measure, DBP ND were not evaluated. However, recent data from D 2/3 blocking (antipsychotic occupancy) studies inform us that the contribution of the D 2/3 specific component to [ 11 C]FLB 457 binding in the human cerebellum is relatively small (7-14%) compared to the cortex (480%). 12 Consistent with this observation previous [ 11 C]FLB 457-amphetamine studies in humans have not reported a significant reduction in cerebellum V ND . 9, 47, 48 Thus, the methods of this imaging study, which were attentive to inadequate power and the effect of carry over mass, were successful in demonstrating a dose-dependent effect for amphetamine on [ 11 C]FLB 457 BP ND .
Another methodological consideration that deserves discussion is the use of ketamine as a pre-anesthetic in animals for the imaging/microdialysis experiments. Previous PET studies have shown that ketamine when co-administered with amphetamine can lead to a twofold increase in stimulated DA release in the striatum. 49 It is not known whether ketamine has the same modulatory effect on DA release in the prefrontal cortex. Nevertheless, if we were to assume that ketamine pretreatment led to greater amphetamine-induced DA release in the cortex in these studies, it is likely that that a smaller displacement of [ 11 C]FLB 457 binding (that is, less DA release) will be measured in non-anesthetized humans. Somewhat consistent with this notion, the same 0.5 mg kg À 1 dose of amphetamine leads to B16 and 10% reduction in [ 11 C]FLB 457 BP ND in anesthetized primates and non-anesthetized humans. Although its possible that differences in the route of administration of amphetamine (intravenous versus oral) may have contributed to the differential displacement in primates and humans. Nevertheless, it is likely that the relationship between amphetamine-induced increases in dialysate DA and decrease in [
11 C]FLB 457 BP ND is preserved irrespective of anesthesia or route of administration of amphetamine. Thus, [ 11 C]FLB 457-amphetamine studies in humans should be able to use the quantitative relationship established between microdialysis and PET in this study to interpret their data.
The strengths of the microdialysis experiments were the ability to repeat experiments in the same animal after different doses of amphetamine, the use of a post-surgical CT scan to guide probe trajectories to access the frontal cortex, implantation of the probes a day before microdialysis to reduce changes in DA related to acute implantation and simultaneous performance of dialysis during PET scans. The microdialysis experiments demonstrated a dose-dependent increase in dialysate DA for amphetamine in the frontal cortex. The mean increase in dialysate peak DA in this study was 999, 1320 and 2355% after 0.3, 0.5 and 1.0 mg kg À 1 of amphetamine (Table 3) . These results that suggest a linear relationship between amphetamine dose and dialysate peak DA in the frontal cortex are consistent with that observed in the striatum in previous studies (Figure 2) . 1, 2 In this study, DA release (peak DDA) in the striatum (3244%) was 2.5-fold higher than that in the frontal cortex (1320%). Two previous microdialysis studies in non-human primates suggest a 4-and 10-fold higher DA release in the striatum relative to the frontal cortex. 13, 50 One reason for a lack of consistency in the ratio of striatal/frontal cortical DA release between studies is the greater between-subject variability in DA release observed in the frontal cortex as opposed to the striatum. 12 This issue is likely exacerbated in non-human primate studies, which evaluate a small number of animals. In rodent studies where sample sizes are relatively large, amphetamine studies support a striatal/frontal cortical DA release ratio of 2-4, 51, 52 which is in line with the values reported in this study.
One of the limitations of the current study was the lack of measurements of DA release in prefrontal cortical subdivisions such as dorsolateral prefrontal cortex, orbital frontal cortex, medial prefrontal cortex and anterior cingulate cortex. We decided against this approach as the [ 11 C]FLB 457 reproducibility studies in non-human primates showed a relatively high test-retest variability for BP ND in the prefrontal cortical subdivisions when they were analyzed using the method used in the human studies. This is likely due to the poor separation of gray and white matter voxels in the primate cortex. Nevertheless, considering that the magnitude of amphetamine-induced displacement of [ 11 C]FLB 457 in the prefrontal cortical subdivisions in humans is not that different (B10% in an extended human [ 11 C]FLB 457-amphetamine dataset in n ¼ 24 healthy individuals, unpublished data) and that DA in different prefrontal cortical regions likely comes from axons from the same population of DA neurons it seems reasonable to use the data that was acquired from the frontal cortex region as a whole in this study to inform the magnitude of DA release in the human subdivisions.
In summary, the results of this study support a linear relationship between increases in dialysate DA and reduction in 
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